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The tandem BRCT domains of BRCA1 and MDC1
facilitate protein signaling at DNA damage foci
through specific interactions with serine-phosphory-
lated protein partners. The MDC1 BRCT binds pSer-
Gln-Glu-Tyr-COO at the C terminus of the histone
variant gH2AX via direct recognition of the C-terminal
carboxylate, while BRCA1 recognizes pSer-X-X-Phe
motifs either at C-terminal or internal sites within
target proteins. Using fluorescence polarization
binding assays, we show that while both BRCTs
prefer a free main chain carboxylate at the +3 posi-
tion, this preference is much more pronounced in
MDC1. Crystal structures of BRCA1 and MDC1
bound to tetrapeptide substrates reveal differences
in the environment of conserved arginines (Arg1699
in BRCA1 and Arg1933 in MDC1) that determine the
relative affinity for peptides with –COO versus
–CO-NH2 termini. A mutation in MDC1 that induces
a more BRCA1-like conformation relaxes the binding
specificity, allowing the mutant to bind phosphopep-
tides lacking a –COO terminus.
INTRODUCTION
The maintenance of genomic integrity in the face of genotoxic
events relies on nuclear signaling systems that coordinate the
repair of DNA damage with regulation of the cell cycle and
apoptosis. Protein phosphorylation plays a central part in these
signaling pathways, involving conserved Ser/Thr protein kinases
and classes of proteins that have evolved to specifically
recognize phosphorylated protein targets (Mohammad and
Yaffe, 2009).
One of the most important classes of protein modules that
recognize phosphoproteins in the DNA damage response are
BRCT domains, named after the tandem repeats found at the
C terminus of the breast cancer-associated protein, BRCA1
(Callebaut and Mornon, 1997; Koonin et al., 1996; Miki et al.,
1994). This region is critical to the tumor suppressor function of
BRCA1, as cancer-associated mutations tend to cluster in this
region of the protein (Easton et al., 2007; Futreal et al., 1994;
Miki et al., 1994). The tandem BRCA1 BRCT repeats pack inStructure 18, 167a head-to-tail manner (Williams et al., 2001), forming a single
protein domain that specifically binds peptide motifs containing
a phosphoserine followed by a phenylalanine 3 residues toward
the C terminus (Manke et al., 2003) (Figure 1A). Recognition of
pSer-x-x-Phe motifs govern interactions between BRCA1 and
target proteins such as the BRIP1/BACH1 DNA helicase (Yu
et al., 2003), the DNA end processing nuclease CtIP (Yu and
Chen, 2004), and the double strand break-associated protein
Abraxas (Kim et al., 2007; Liu et al., 2007; Wang et al., 2007).
The phosphoserine of the peptide target is recognized by
a cluster of residues in the N-terminal BRCT repeat that provides
ligands for the phosphate, while the phenylalanine is recognized
by a pronounced pocket at the interface of the two repeats
(Clapperton et al., 2004; Glover et al., 2004; Shiozaki et al.,
2004; Williams et al., 2004) (Figure 1B). Critical for recognition
of the phenylalanine is Arg1699, which interacts with the main
chain of the peptide phenylalanine, positioning the side chain
in the hydrophobic recognition pocket. The phenylalanine recog-
nition pocket is essential for BRCA1 tumor suppression as is
illustrated by the finding that the missense mutant M1775R
specifically perturbs the structure of this pocket and abrogates
phosphopeptide recognition (Williams and Glover, 2003).
Another BRCT protein, MDC1, plays an essential early role in
signaling from DNA double strand breaks through its recognition
of the ATM-phosphophorylated histone variant, H2AX (Goldberg
et al., 2003; Lou et al., 2003; Stewart et al., 2003). Phospho-
H2AX (also known as gH2AX) ultimately leads to the recruitment
of DNA repair, replication, and cell cycle regulatory factors to the
site of the damage (Sedelnikova et al., 2003; Stucki and Jackson,
2006). The C-terminal phosphorylated tail of gH2AX serves as
the specific binding site for MDC1 (Lee et al., 2005; Stucki
et al., 2005), which initiates a cascade of phosphorylation and
ubiquitination events that recruit BRCA1 to the double strand
break foci (Yan and Jetten, 2008).
Intriguingly, the BRCA1 and MDC1 tandem BRCT repeats
recognize very similar phosphopeptide substrates: pSer–x-x-
Phe/Tyr for BRCA1 and pSer-Gln-Glu-Tyr for MDC1. In spite of
this similarity, MDC1 and BRCA1 bind different phosphorylated
proteins to fulfill distinct roles in the DNA damage response.
Themost striking difference in specificity is likely the high degree
of selectivity that MDC1 shows for the C-terminal carboxylate of
the gH2AX tail, which is precisely conserved at the +3 position
with respect to the pSer in all H2AX orthologs from humans to
yeast. Here we probe the structural basis for the differences in
selectivity for the phosphopeptide C-terminal structure between
BRCA1 and MDC1. We demonstrate, through structural and–176, February 10, 2010 ª2010 Elsevier Ltd All rights reserved 167
Figure 1. Structure of the BRCA1 BRCT Domain Bound to Phosphopeptide Targets
(A) Overview of the structure of the BRCA1BRCT domain bound to phospho-BACH1 (residues 986–995). BACH1peptide is shown as cyan cartoon with Ca atoms
shown as spheres and the phosphoserine and phenylalanine (+3) residues shown as sticks.
(B) An alignment of the BRCA1/BACH1 structure (teal) with that of BRCA1BRCT bound to its minimal tetrapeptide recognition sequence (pSPTF-CONH2) (green).
The BRCT domain is shown as a cartoon and the peptides are shown as sticks. Important residues involved in peptide binding are labeled and hydrogen bonds
are shown with dashed lines.
Structure
Peptide Binding Specificities of BRCT Domainsbinding analysis of wild-type (WT) and mutant BRCT domains,
characteristics that give MDC1 a large degree of specificity for
the free C terminus of H2AX and in contrast, the seemingly
more promiscuous nature of BRCA1.RESULTS
Specificity of BRCA1 and MDC1 BRCT Domains
for the C Termini of their Phosphopeptide Targets
The MDC1 BRCT domain specifically binds the gH2AX peptide
tail, pSer-Gln-Glu-Tyr-COO, in a manner that is highly depen-
dent on the free C terminus at the +3 position. In contrast,
BRCA1 has been shown to bind internal pSer–x-x-Phe peptide
targets (as in BACH1 or CtIP) as well as the pSer-x-x-Phe motif
at the C terminus of the protein (as in Abraxas). In order to
compare the specificities of the BRCA1 and MDC1 BRCT
domains for the chain termini at the +3 position, we used
a competitive fluorescence polarization (FP) assay (Lokesh
et al., 2006). Each domain was bound to a fluorescein-labeled
phosphopeptide target specific for that BRCT domain. The
BACH1 target sequence was used for BRCA1, while the
gH2AX tail peptide was used for MDC1. The labeled peptide
was then competed off the BRCT domain using tetrapeptides
containing the minimal recognition sequences: pSPTF for
BRCA1 and pSQEY for MDC1. To test the role of the C terminus
in peptide binding, competition experiments were performed
with tetrapeptides containing either free carboxylate C termini
or amidated (and therefore uncharged) C termini, and the inhibi-
tion constants (Ki) of each of the tetrapeptides was determined.
The results demonstrate that the tetrapeptide pSQEY-COO
competes very effectively for binding to MDC1, with a Ki of
1.1 ± 0.1 mM (Figure 2A). However, amidation of the C-terminal168 Structure 18, 167–176, February 10, 2010 ª2010 Elsevier Ltd Alltail (pSQEY-CONH2) reduced the Ki approximately 50-fold, to
51 ± 1 mM. These findings are consistent with previously reported
values from direct binding measurements (Stucki et al., 2005).
BRCA1 also showed a significant, although less dramatic, pref-
erence for a negatively charged C-terminal carboxylate at the +3
position. The tetrapeptide pSPTF-COO inhibited binding of the
fluorescein-labeled phosphopeptide very effectively (Ki = 3.7 ±
0.3 mM) while the C-terminally amidated version (pSPTF-
CONH2) inhibited binding about 7-fold less efficiently (Ki = 25 ±
5 mM) (Figure 2B). The micromolar Ki value for the C-terminally
amidated tetrapeptide is similar to previously reported values
using direct binding measurements (Lokesh et al., 2006).Structural Mechanism of Recognition of Carboxyl
Chain Termini by BRCA1
To investigate the differences in affinity of BRCA1 for a free
carboxylate versus an amidated tail at the +3 position, we solved
the crystal structures of both tetrapeptides bound to the BRCA1
BRCT domain. Complexes of BRCA1 BRCT bound to either tet-
rapeptide crystallized in the same space group as the unli-
ganded BRCT domain (Williams et al., 2001) and the structures
were determined to 2.70 A˚ (Table 1). The amidated tetrapeptide
(pSPTF-CONH2) binds in a manner that is almost identical to that
observed in the previously reported structures of BRCA1 BRCT
bound to longer BACH1 peptides (Clapperton et al., 2004)
(Figure 1B). In these structures, the backbone oxygen of the
C-terminal amide makes a single hydrogen bond with the N3 of
the conserved Arg1699. The peptide amide nitrogen rotates
vertically above the oxygen, in a position that minimizes clashes
with the terminal NH2 of the guanidinium group of Arg1699. In
the structure of free carboxylate peptide (pSPTF-COO) the
C-terminal tail rotates slightly, so that the free carboxylate grouprights reserved
Figure 2. Effect of the Structure of the Phosphopeptide C Terminus on Interactions with BRCA1 and MDC1
(A) FP experiments comparing the ability of gH2AX-derived tetrapeptides with amidated or free C-terminal ends to compete for MDC1 binding with a native
gH2AXphosphopeptide. Ki values are calculated as described in Experimental Procedures. The dashed line indicates a tetrapeptidewith an amidatedC terminus,
and the solid line indicates a peptide with a free carboxylate C terminus. Error bars indicate the standard deviation of at least three separate measurements.
(B) FP experiments comparing the ability of BACH1-derived tetrapeptides with amidated or free C-terminal ends to compete for BRCA1 binding with a native
BACH1 phosphopeptide. The dashed line indicates a tetrapeptide with an amidated C terminus and the solid line indicates a tetrapeptide with a free carboxylate
C terminus. Error bars indicate the standard deviation of at least three separate measurements.
(C) A structural alignment of BRCA1 BRCT in complex with the BACH1 tetrapeptide amidated at the C terminus (green) with the structure of a complex containing
tetrapeptide with a C-terminal carboxylate (magenta). Important hydrogen bonds are indicated with dashed lines.
(D) Structure of the MDC1 BRCT domain bound to gH2AX. Hydrogen bonds and salt bridges involved in recognition of the gH2AX C terminus are shown with
dashed lines.
Structure
Peptide Binding Specificities of BRCT Domainscan form a double salt bridge with the guanidinium group of
Arg1699 (Figure 2C). The enhanced interaction of the free
carboxylate group with Arg1699 compared with the amidated
C terminus likely explains the increased Ki of the free carboxylate
tetrapeptide for the BRCA1 BRCT.
A Network of Salt Bridges Controls the Specificity
of Recognition for Target Peptide Chain Termini
A comparison of the structure of the MDC1 BRCT domain bound
to the gH2AX tail (Stucki and Jackson, 2006) with the BRCA1
BRCT bound to the pSPTF-CONH2 and pSPTF-COO
 tetrapep-
tides suggests a mechanism that might explain the enhanced
specificity of MDC1 for a free C-terminal carboxylate group
(Figures 2C and 2D). In all the structures, a conserved arginineStructure 18, 167residue (Arg1699 in BRCA1 and Arg1933 in MDC1) contacts the
backbone of the +3 residue. In the structures of BRCA1 and
MDC1 bound to peptides with free carboxylate termini, the anal-
ogous arginine residuesmake similar, double salt bridge interac-
tions with the peptide C-terminal carboxylate and are therefore
likely key in recognition of the peptide C terminus. Differences
in the environment of these arginine residues thereforemay regu-
late the differential recognition of the peptide backbone. In both
BRCT domains, the arginine is largely buried and is held in place
through internal salt bridging interactions. In BRCA1, Arg1699
interacts with both Asp1840 and Glu1836. In MDC1, Glu2063 is
equivalent to BRCA1 Glu1836; however, Asp1840 in BRCA1
has been replaced with a threonine in MDC1 (Thr2067). As
a result, Arg1933 forms a dual salt bridge interaction with the–176, February 10, 2010 ª2010 Elsevier Ltd All rights reserved 169
Table 1. Data Collection and Refinement Statistics





Space group p6122 p6122 p6122 p6122 p212121
Cell dimensions
a, b, c (A˚) 115.07, 115.07, 123.25 114.42, 114.42, 123.00 114.57, 114.57, 123.19 114.34, 114.34, 123.87 55.64, 74.58, 103.41
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 90
Wavelength (A˚) 0.97934 0.97934 0.97934 0.97934 1.11587
Resolution (A˚) 50–2.70 50–2.70 50–2.80 50–3.0 50–1.33
2Rsym
a 6.3 (51.3)b 6.1 (55.7)b 6.4 (57.1)b 8.3 (56.1)b 5.0 (48.9)b
I/sI 24.3 (2.68)b 49.7 (2.35)b 50.1 (2.55)b 37.8 (3.37)b 23.7 (2.7)b
Completeness (%) 99.1 (99.4)b 99.3 (94.0)b 99.5 (96.3)b 99.9 (99.4)b 98.3 (95.7)b
Redundancy 6.8 (5.6)b 19.2(7.7)b 19.5 (9.1)b 20.2 (14.1)b 3.8 (3.7)b
Refinement
Resolution (A˚) 29.44–2.70 35.8–2.70 37.9–2.80 38.7–3.0 37.9–1.33
No. of reflections 13,654 13,511 12,190 10,133 97,828
Rwork/Rfree 24.7/29.6 25.9/29.9 25.0/28.0 22.4/28.8 18.2/20.2
No. of atoms
Protein 1731 1742 1730 1730 3212
Water 18 12 19 6 469
Nickel 1 1 1 1 0
Chloride 1 1 1 1 0
Overall B factor (A˚2) 50 49 49 57 15
Rmsd
Bond lengths 0.008 0.006 0.007 0.007 0.008
Bond angles 1.11 1.03 1.02 1.06 1.30
Ramachandran
Preferred (%) 90.5 86.7 86.7 85.2 99.7
Allowed (%) 9.5 13.3 13.3 14.8 0.3
Disallowed (%) 0 0 0 0 0
aRsym =
Pj(Ihkl)  < I > j /
P
(Ihkl), where Ihkl is the integrated intensity of a given reflection.
b Values in parentheses are for the highest resolution shell.
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Peptide Binding Specificities of BRCT Domainsconserved Glu2063. We suggest that the difference in the envi-
ronment of the analogous arginine residues impacts recognition
of the C terminus of the phosphopeptide chain. The arrangement
observed in MDC1 allows the Arg1933 guanidinium group to
make a dual salt bridging interaction with a highly favorable
geometry. In contrast, in BRCA1, the shift in Glu1836 positions
one of its carboxylate oxygens closer to the peptide +3 carbox-
ylate (4.5 A˚ in BRCA1 versus 5.5 A˚ in MDC1). This difference
may help to explain the reduced selectivity of BRCA1 for a target
with a free carboxylate group at the +3 position.
The structures of BRCA1 BRCT indicate that the interaction of
Arg1699 with Asp1840 influences its interactions with Glu1836
and therefore may affect peptide binding selectivity. To test
the importance of Asp1840 in BRCA1 and the analogous
Thr2067 in MDC1, we created BRCA1 and MDC1 mutants in
which these residues were exchanged for the corresponding
residue in the other BRCT protein, generating the mutants
BRCA1 D1840T and MDC1 T2067D. The effects of these muta-
tions on the structures and peptide binding specificities of the
mutant proteins were determined.170 Structure 18, 167–176, February 10, 2010 ª2010 Elsevier Ltd AllStructure and Peptide Binding Specificity of BRCA1
D1840T
The BRCA1 D1840T mutant in complex with both the pSPTF-
CONH2 and pSPTF-COO
 peptides was crystallized and the
structures were determined to 2.8 and 3.0 A˚ resolution, respec-
tively (Table 1). The structures reveal that the D1840T substitu-
tion facilitates an MDC1-like interaction between Arg1699 and
Glu1836 in which the two side chains contact one another
through double salt bridging interactions (Figures 3A and 3B).
In the BRCA1-BRCT/pSPTF-COO structure, the C-terminal
peptide terminus rotates almost completely horizontal relative
to Arg1699, resulting in a more optimal salt bridge compared
to the WT structure.
FP was used to assess the effect of the BRCA1 D1840T muta-
tion on recognition of the pSPTF-COO and pSPTF-CONH2
peptides (Figure 3C). The Ki of D1840T BRCA1 for pSPTF-
CONH2 increases to 12 ± 2 mM, while the Ki for pSPTF-COO

increases to 1.6 ± 0.3 mM. The results indicate a subtle 2-fold
increase in the binding affinity of the mutant for either tetra-
peptide compared to WT BRCA1. In spite of the fact thatrights reserved
Figure 3. Binding and Structural Characteristics of
BRCA1 BRCT D1840T in Complex with Tetrapepti-
des Containing Amidated or Free C Termini
(A) Structural features of BRCA1D1840T bound to pSPTF-
CONH2. Dashed lines indicate hydrogen bonds.
(B) Structural features of BRCA1D1840T bound to pSPTF-
COO. Dashed lines indicate hydrogen bonds.
(C) Competition assay of free and C-terminally amidated
tetrapeptides. The solid line indicates the tetrapeptide
with an amidated C terminus and the dashed line indicates
the tetrapeptide with a free carboxylate C terminus. Ki is
calculated from the competition curve as described in
Experimental Procedures. Error bars indicate the standard
deviation of at least three separate measurements.
Structure
Peptide Binding Specificities of BRCT Domainsthe mutation has induced a more MDC1-like conformation in the
mutant, there is no corresponding increase in the selectivity of
the mutant for peptides with a free C-terminal carboxylate.
Structure and Peptide Binding Specificity of MDC1
T2067D
FP spectroscopywas used to characterize the changes in affinity
and specificity induced by the T2067D mutation in MDC1
(Figure 4A). Direct binding experiments suggested a small, 2-
fold decrease in the affinity of the T2067D mutant for that of
the fluorescein-labeled gH2AX peptide compared to WT (data
not shown). However, no significant differences between the
mutant and WT were observed in the context of competition
studies using the gH2AX tetrapeptide (Ki = 1.4 ± 0.2 mM versus
1.1 ± 0.1 mM), suggesting the mutation induces little if any
change in recognition of the gH2AX C-terminal carboxylate. In
contrast, the amidated gH2AX peptide (pSQEY-CONH2) was
a much more effective inhibitor of MDC1 T2067D than WT
MDC1, with a nearly 4-fold enhanced Ki compared to the WT.
Thus unlike BRCA1D1840T,MDC1 T2067D induces a significant
change in the specificity of the BRCT domain for the C terminus
of the peptide tail. While WT MDC1 shows a 50-fold preference
for the gH2AX tail with a free C-terminal carboxylate versus an
amidated end, the T2067D mutant shows only a 10-fold prefer-
ence, very similar to that observed for BRCA1.
To understand the structural basis for this change in speci-
ficity, we crystallized and determined the structure of MDC1Structure 18, 167–176, February 10T2067D bound to the gH2AX tetrapeptide
pSQEY-CONH2 at 1.33 A˚ resolution. This crystal
form is isomorphous with that of the unliganded
MDC1 BRCT domain previously determined
(Lee et al., 2005) and contains two BRCT-tetra-
peptide complexes in the asymmetric unit
(Table 1). One complex in the asymmetric unit
reveals an interaction between Arg1933 and
Asp2067 that is similar to the salt bridging
pattern of the analogous residues in BRCA1
(Figure 4B). However, unlike BRCA1, Glu2063
adopts a rotamer not observed in either WT
MDC1 or BRCA1 such that it no longer directly
contacts Arg1933. Instead, a pair of water mole-
cules bind in the space created between
Arg1933, Glu2063, and Asp2067 and the
peptide C terminus. This arrangement allowsthe Arg to shift lower in the binding pocket compared to the
WT, increasing the distance between the amidated C terminus
of the peptide and the Arg1933 guanidium, while maintaining
hydrogen bonding interactions with the peptide main chain
carbonyl group. The water molecules may also stabilize peptide
binding through bridging hydrogen bonds between the terminal
amide of the peptide and Glu2063. In the other complex in the
asymmetric unit, a second set of alternative conformations are
observed for Glu2063 and Asp2067. In this alternative conforma-
tion, it is Glu2063 that forms a direct salt bridge contact to
Arg1933 in a manner that is similar to WT BRCA1, while the
Asp2067 swings away from the Arg1933 and contacts Lys2071
(see Figure S1B available online). Thus, the T2067D mutation in
MDC1 does induce a more BRCA1-like recognition of phospho-
peptides, through a relaxation of the requirement for a C-terminal
main chain carboxylate at the peptide +3 position. This is accom-
plished through a shift to a more BRCA1-like conformation in the
mutant, as well as an increase in the flexibility and hydration of
the recognition surface, which results in a significant enhance-
ment in the affinity of the mutant MDC1 for the C-terminally ami-
dated phosphopeptide.
The MDC1 BRCT Is Highly Selective for
Ser139-Phosphorylated gH2AX and Does
Not Bind Alternative Phosphopeptide Targets
Recent studies have demonstrated that the +3 C-terminal tyro-
sine residue of H2AX (Tyr142) is phosphorylated in a manner, 2010 ª2010 Elsevier Ltd All rights reserved 171
Figure 4. Binding and Structural Characteristics of MDC1 BRCT
T2067D in Complex with gH2AX Tetrapeptides Containing Amidated
or Free C Termini
(A) Competition assay of T2067D in complex with free and amidated tetrapep-
tides. Dashed line indicates an amidated tetrapeptide and the solid line indi-
cates a free carboxylate tetrapeptide. The Ki is calculated from the competition
binding curve as described in Experimental Procedures. Error bars indicate the
standard deviation of at least three separate measurements.
(B) Structural features and water network of T2067D bound to pSQEY-CONH2
as shown in chain A (gray) aligned with WT MDC1 (orange). Dashed lines in
orange and gray indicate hydrogen bonds. Distance shown in red indicates
the increased distance between Arg1933 NH2 and the tetrapeptide C-terminal
amide observed in the mutant structure.
Structure
Peptide Binding Specificities of BRCT Domainsthat is coordinated with the phosphorylation status of Ser139
(Cook et al., 2009; Xiao et al., 2009). In undamaged chromatin,
Tyr142 is phosphorylated by the WSTF component of the
WSTF-SNF2H (WICH) chromatin remodeling complex (Xiao
et al., 2009). In response to a DNA double strand break, this
phosphorylation is lost due to the action of the EYA phospha-
tase, and H2AX is subsequently phosphorylated at Ser139 to172 Structure 18, 167–176, February 10, 2010 ª2010 Elsevier Ltd Allallow the subsequent binding of MDC1. The balance of these
two phosphorylation events may help direct the damaged cell
to either an MDC1-dependent DNA repair/cell survival pathway
or an apoptotic pathway (Cook et al., 2009).
We used FP spectroscopy to quantitate the effects of Tyr142
phosphorylation on interactions with the MDC1 BRCT domain.
Our results show a profound, >300-fold reduction in the affinity
of MDC1 BRCT-gH2AX interactions upon phosphorylation of
Tyr142 (Figure 5A), which agrees with the results of peptide
pull-down experiments (Xiao et al., 2009). To understand the
structural basis for this discrimination, we modeled the pSer/
pTyr tetrapeptide (pSQEpY-COO) into the MDC1 binding
pocket (Figure 5B). The modeling suggests that the phosphate
of pTyr142 would clash with either the MDC1 specificity
loop or the absolutely conserved Gln140 depending on the
pTyr rotamer.
The MDC1 BRCT domain has also been shown to specifically
bind the C-terminally phosphorylated tail of topoisomerase IIa,
an interaction that specifically regulates the DNA decatenation
cell cycle checkpoint (Luo et al., 2009). The sequence of the top-
oisomerase IIa peptide (pSDEDDLF-COO) is unrelated to that
of gH2AX. We used FB to test for interactions of this unusual
target with the MDC1 BRCT but were unable to detect any
binding activity (data not shown). The previously reported
binding activity may therefore represent an interaction that
requires additional contacts, perhaps involving other regions of
the proteins or additional protein cofactors.
DISCUSSION
Our results provide structural insight into the central role played
by a conserved arginine (BRCA1 Arg1699 andMDC1 Arg1933) in
the recognition of the phosphopeptide +3 residue by tandem
BRCT repeats. We show that the details of salt bridging interac-
tions between this arginine and acidic residues that bridge the
interface between the BRCT repeats modulate the orientation
of this residue and its interactions with the phosphopeptide
backbone.
Arg1699 likely plays an especially critical role in BRCA1 func-
tion as three distinct missense variants (R1699W, R1699L, and
R1699Q) have been uncovered at this position through breast
cancer screening programs (see http://research.nhgri.nih.gov/
bic/ for a listing of BRCA1 variants). Pedigree analysis suggests
both R1699W and R1699Q are associated with an increased
cancer risk, and these variants are functionally defective in
a BRCA1 transcription assay (Vallon-Christersson et al., 2001)
and in their ability to bind a pSer-x-x-Phe peptide in a pull-
down assay (Williams et al., 2004). The R1699Q mutation is
particularly interesting, since it should be able to participate in
hydrogen bonding interactions with the peptide +3 backbone
that could mimic the salt bridging observed in the WT. The fact
that this mutant shows peptide binding defects indicates that
the ability to form salt bridges, either with the phosphopeptide
or with Glu1836 andAsp1840, and not simply hydrogen bonding,
is critical for its function. Interestingly, an E1836K variant has
also been found through breast cancer screening. We suggest
that this variant could perturb the orientation of Arg1699 through
electrostatic repulsion with the Lys1836 and thereby impact
phosphopeptide recognition.rights reserved
Figure 5. Binding Data and Model of gH2AX Peptide Containing Phosphorylated Tyr142 Bound to MDC1 BRCT
(A) Competition assay of WT MDC1 BRCT with gH2AX tetrapeptide with and without phosphorylation of Tyr142. Dashed line indicates the gH2AX tetrapeptide
(pSQEY-COO) and the solid line indicates the tetrapeptide with phosphorylated Tyr142 (pSQEpY-COO). Error bars indicate the standard deviation of at least
three separate measurements.
(B) Structural model showing the implications of a phosphorylated Tyr142 in the +3 binding pocket. Two rotomers of the phosphate group of pTyr142 are shown,
with a surface representation of nearby residues that would potentially clash with the phosphate group labeled in red.
Structure
Peptide Binding Specificities of BRCT DomainsArg1933 in MDC1, like Arg1699 in BRCA1, is also necessary
for recognition of the phosphopeptide main chain at the +3 posi-
tion. In spite of the structural similarity of the BRCA1- andMDC1-
phosphopeptide complexes, MDC1 shows a dramatic, 50-fold
selectivity for peptides with a terminal main chain carboxylate
at the +3 position compared to peptides with an amidated
C terminus. In contrast, BRCA1 shows a much reduced,
7-fold selectivity for a main chain carboxylate at the peptide
+3 position (Figure 6A). Introduction of a T2067D substitution
inMDC1 induces a significant increase in the affinity of a C-termi-
nally amidated gH2AX phosphopeptide such that the binding
preference for a C-terminal carboxylate versus an amide drops
to 10-fold (Figure 6A). The high resolution structure of this variant
in two different crystal environments reveals an overall more
BRCA1-like conformation and additional flexibility near
Arg1933. This relaxation of the MDC1 structure allows a shift in
the position of the Arg1933 guanidium group that relieves the
electrostatic repulsion with the terminating amide group at the
phosphopeptide C terminus that would otherwise occur.
Interestingly, the complimentary substitution in BRCA1,
D1840T, does not induce an MDC1-like enhancement in the
preference for a main chain carboxylate at the phosphopeptide
+3 position. The reason for this likely is explained by differences
in the way in which the +3 tyrosine is positioned in the specificity
pocket of BRCA1 and MDC1 (Figure 6B). In both proteins, key
interactions with the +3 side chain are made by residues from
the b10-a100 loop. Met1775 in BRCA1 makes the closest contact
to the phenylalanine side chain at +3, while Pro2009 contacts the
+3 tyrosine side chain in MDC1. In MDC1, these interactions
place the +3 Tyr carboxylate such that it contacts the Arg1933
guanidinium group in a nearly co-planar orientation. In the
BRCA1 complex, the +3 Phe sits lower in its binding pocket
and its main chain approaches the Arg1699 guanidinium inStructure 18, 167a more orthogonal manner, 20 offset from the angle of
approach observed in MDC1. The more favorable hydrogen
bonding geometry associated with the in-line approach of the
C-terminal peptide carboxylate on the Arg1933 guanidinium
group in MDC1 explains the enhanced affinity of MDC1 for the
carboxylated chain terminus compared to BRCA1. In contrast,
the BRCA1 orientation provides more flexibility, allowing for
binding of extended peptide chains. In the BRCA1 orientation,
a small rotation of the c torsion angle of the C-terminal residue
is sufficient to shift the amidated C terminus of the peptide
away from the Arg1699 guanidinium group. However, in the
MDC1 orientation a similar rotation is not sufficient to minimize
the clash between the backbone and the Arg1933 guanidinium
without a more significant reorganization of the interface. This
likely explains MDC1’s strong discrimination against binding
peptide targets with extensions beyond the +3 position (Lee
et al., 2005; Stucki et al., 2005).
The precise and rather rigid recognition of the peptide
C-terminal carboxylate is central to the ability of MDC1 to
mediate interactions with H2AX and for the modulation of these
interactions through phosphophorylation of H2AX at Tyr142.
pTyr142 is an important H2AX mark in undamaged chromatin,
where one of its roles is to likely block binding of MDC1 (Xiao
et al., 2009; Cook et al., 2009). The anchoring of the Tyr142
through strong interactions with Arg1933, as well as van der
Waals contacts with Pro2009, fixes the tyrosine on MDC1
such that its phosphorylation cannot be accommodated in the
binding pocket.
The recognition of the C-terminally phosphorylated tail of
H2A/H2AX by BRCT proteins in the DNA damage response is
conserved throughout eukaryotes. In both S. cerevisiae and
S. pombe, 53BP1 orthologs specifically bind the gH2A tail
(.ApSQEL-COO) via their tandem BRCT repeats (Hammet–176, February 10, 2010 ª2010 Elsevier Ltd All rights reserved 173
Figure 6. The Threonine/Aspartic Acid Mutation Affects the Specificity of MDC1 but not BRCA1
(A) A graphical representation showing the magnitude of the preference of each of the recombinant BRCT domains for a free main chain carboxylate at the
+3 position of the phosphopeptide.
(B) The alignment shows MDC1 BRCT in orange and the BRCA1 BRCT D1840T in salmon. Solid black lines indicate the angular change in orientation of the side
chains, and rotation about the c angle is shown by a black arrow. Only the backbone is shown for peptide residues N-terminal to the Phe/Tyr. Surface represen-
tation is shown for Phe (+3) of the BRCA1/pSPTF-CONH2 structure and Pro2009 of the MDC1/H2AX structure. Salt bridging interactions of Arg1699/1933 are
shown with dashed lines.
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Peptide Binding Specificities of BRCT Domainset al., 2007; Kilkenny et al., 2008). The fact that the position of the
H2A C terminus is precisely conserved suggests that this may be
a dominant specificity determinant in the yeast systems.
However, the crystal structure of the BRCT domain of the
S. pombe 53BP1 ortholog Crb2 bound to the gH2A tail indicates
that the gH2A C-terminal carboxylate does not contact Crb2
Arg616 (analogous to Arg1699 in BRCA1). It has been suggested
that in this case chromatin recognition may not only involve
BRCT-gH2A interactions but may also rely on interactions of
the adjacent tandem Tudor domain with lysine-methylated
histones (Kilkenny et al., 2008). Intriguingly, the 53BP1 tandem
BRCT domain also binds gH2AX in vitro, raising the possibility
that 53BP1 may recognize nucleosomes presenting methyl-
lysine andgH2AXhistone tails during theDNAdamage response.
Given the conformationally restrained yet structurally diverse
nature of the BRCA1 and MDC1 peptide-binding grooves, it
may be possible to develop inhibitors that are specific for a
particular BRCT domain. Indeed, preliminary studies have iden-
tified both peptide and small molecule inhibitors of the BRCA1174 Structure 18, 167–176, February 10, 2010 ª2010 Elsevier Ltd AllBRCT domain (Lokesh et al., 2007, 2006; Simeonov et al.,
2008). Here we have defined an important determinant of spec-
ificity between BRCA1 and MDC1 that could be utilized in the
rational design of specific BRCT inhibitors. Such inhibitors could
provide useful tools for the study of the role of specific BRCT
domains and potentially could provide new routes to modulate
the DNA damage response in the treatment of cancer.EXPERIMENTAL PROCEDURES
BRCT Plasmids and Purification
BRCA1 BRCT WT (residues 1646–1859), used in both FP and crystallization
experiments, was expressed as an untagged recombinant protein in the
plasmid pLM1-CD6. This plasmid was used as a template to clone BRCA1
BRCT D1840T using PCR mutagenesis, which was then ligated into the
same plasmid. Both proteins were expressed in E. coli BL21 Gold (Invitrogen)
for 15 hr at 22C and purified as previously described (Williams et al., 2001).
Purified BRCA1 BRCT was buffer exchanged into crystallization buffer
[5 mM Tris HCl (pH 7.5) and 400 mMNaCl] using spin concentration and quan-
tified using a BCA assay.rights reserved
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Peptide Binding Specificities of BRCT DomainsMDC1 WT (1891–2089) was expressed as a maltose binding protein fusion
protein using pKM596 (NEB). This construct was then used as a template to
cloneMDC1 BRCT T2067D using PCRmutagenesis and Gateway (Invitrogen).
The proteins were overexpressed in E. coliBL21Gold at 20C for 16 hr, and the
cell pellets were then resuspended and sonicated. The lysate was cleared by
ultracentrifugation at 40,000 3 g for 1 hr. The cleared lysate was further puri-
fied with an amylose resin affinity column (NEB). MDC1 used for crystallization
was then cleaved using Actev protease (Invitrogen) and the maltose binding
protein tag was removed using anion exchange chromatography. Purified
MDC1 BRCT was buffer exchanged into crystallization buffer [10 mM Tris-
HCl (pH 7.5), 150 mMNaCl, and 1 mMDTT] and quantified using a BCA assay.
Fluorescence Polarization
Fluorescein-labeled peptides were obtained from the Alberta Peptide Institute
and are as follows: BACH1 peptide, fluorescein-GGSRSTpSPTFNK-CONH2;
gH2AX peptide, fluorescein-KKATQApSQEY-COO. Fluorescein peptide
binding to BRCA1 and MDC1 BRCT domains was verified by titrating an
increasing concentration of protein into a constant concentration of labeled
peptide. Fluorescein fluorescence was excited at a wavelength of 485 nm
and the emission was measured at 538 nm on a PerkinElmer Envision plate
reader. The change in polarization was graphed as a function of the log of
the protein concentration, and the dissociation constant (KD) was obtained
from the resulting sigmoidal curve. The fluorescein-labeled peptidewas shown
to have a similar KD as previously reported values using both FP and direct
binding methods (Figure S2) (Lokesh et al., 2006; Stucki et al., 2005). Binding
constants of the tetrapeptides were then determined using a competition
assay, where the ability of the tetrapeptide to compete off the labeled peptide
was measured. The concentration of protein used in the competition assay
was determined based on the KD of the labeled peptide to its corresponding
protein. The IC50 was obtained from the competition assay and the Ki was
then calculated using the Coleska-Wang equation (Nikolovska-Coleska
et al., 2004). For all assays, a concentration of 100 nM of labeled peptide
was used in a reaction volume of 20 ml. Accurate concentrations of the tetra-
peptides were determined by amino acid analysis.
Crystallization and Data Collection
The BRCA1 BRCT WT in complex with pSPTF-CONH2 was crystallized using
the sitting drop vapor diffusion method. BRCA1 BRCT WT was incubated on
ice with an equimolar amount of pSPTF-CONH2 for3 hr. Crystals were grown
by mixing 2 ml of BRCA1 BRCT WT [10 mg ml1 protein, 5 mM Tris-HCl (pH
7.5), and 400 mM NaCl] with 1 ml of well solution [0.1 M Tris-HCl (pH 7.3),
0.4 M Li2SO4, and 10 mM NiCl2]. BRCA1 BRCT WT in complex with pSPTF-
COO grew in identical conditions. Crystals of BRCA1 BRCT D1840T in
complex with both tetrapeptides grew in very similar conditions to the WT
protein, but preferred a pH between 8.3 and 8.5. Crystals were present in
the drops after several days andwere large enough to loop after approximately
2 weeks. Crystals were cryoprotected in well solution supplemented with 26%
glycerol and approximately 250 mM tetrapeptide, and then looped and flash
frozen using liquid nitrogen. Data were collected at beamline CMCF 08ID-1
at the Canadian Light Source.
The MDC1 BRCT T2067D in complex with pSQEY-CONH2 was crystallized
using the hanging drop vapor diffusion method. MDC1 BRCT T2067D was
incubated on ice with an equimolar concentration of pSQEY-CONH2 for
approximately three hours. Crystals were grown by adding 1 ml of MDC1
BRCT T2067D (7.5 mg ml1, 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM
DTT) and 1 ml well solution (24% PEG 8000 and 0.1 M HEPES pH 8.0). Plates
were present after approximately one week, and were looped using Mitegen
MicroMesh. Crystals were cryoprotected in well solution supplemented with
26% glycerol and approximately 250 mMpSQEY-CONH2. Data were collected
at beamline 8.3.1 at the Advanced Light Source.
Model Building and Refinement
BRCA1 WT and D1840T (1846–1859) complex structures were indexed and
scaled using HKL2000 (Otwinowski and Minor, 1997). Crystals grew in the
space group P6122 with one molecule in the asymmetric unit. The BRCA1
BRCT structures were solved with molecular replacement (Phaser) (McCoy,
2007) using a BRCA1/BACH1 peptide complex (PDB ID: 1T15) as starting
model. The first three residues (1846–1848) were not visible in the electronStructure 18, 167density. Electron density for the tetrapeptides was clear and the ligand was
modeled in to the phosphate binding pocket. The occupancies of the tetrapep-
tides in each model were adjusted to 70%–80% to give reasonable B factors.
Structures were refined using TLS and restrained refinement in REFMAC (Mur-
shudov et al., 1997; Winn et al., 2001, 2003). The TLS parameters were defined
using chain A as the single TLS group. Electron densities of the +3 binding
region shows a change in side chain positions as a result of the corresponding
mutation previously described (D1840T) (Figure S3). Geometric restraints were
tightened from program defaults to maintain correct geometry.
A strong peak located above the side chains of His1805 and His1673 of
a symmetrymate wasmodeled as a nickel cation coordinating to the imidazole
groups as observed in the previous unbound BRCA1 WT structure (Williams
et al., 2001). Although three other waters were expected to be coordinated
to the nickel, it was not possible to satisfactorily model them into the BRCA1
WT complex structures. However, in the BRCA1 D1840T complex structures,
two waters coordinated to the nickel were modeled with reasonable geometry.
In addition to the nickel peak, another strong peak was located near the
N terminus of the tetrapeptide. Since both sulfate and chloride were present
in the crystallization conditions, it was likely that an anion was bound to the
ammonium cation at the N terminus of the tetra peptide. Chloride was the
only ion that resulted in satisfactory geometry and was refined at the same
occupancy as the tetrapeptide. Model building was done using the program
Coot (Emsley and Cowtan, 2004).
MDC1 T2067D (1891–2089) was indexed and scaled using HKL2000. Crys-
tals grew in the P212121 space group and phases were solved by molecular
replacement using a previous MDC1 BRCT structure (PDB ID: 2ADO). The
electron density for pSQEY-CONH2 was clear, and the ligand was modeled
in easily. The orientation of Glu2063 and Asp2067 in chain A was clear at
1.35 A˚ (Figure S2A). The electron density around chain B indicated an alternate
conformation, in addition to the one in chain A, where Glu2067 interacted with
Arg1933 while Asp2067 rotates away (Figure S2B). However, given the two
conformations present in chain B, the electron density was not quite as clear.
The structure was refined with TLS and restrained refinement using aniso-
tropic B factors in REFMAC. For TLS, the main chain of each molecule in the
asymmetric unit and each tetrapeptide were defined as individual TLS groups.
Residues 1891–2089 were modeled in to chain B, but the final six residues did
not have clear electron density in chain A and could not be modeled.ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited into the
Protein Data bank with the ID codes 3K05 for MDC1 BRCT T2067D/pSQEY-
CONH2, 3K0H for BRCA1 BRCT/pSPTF-CONH2, 3K0K for BRCA1 BRCT/
pSPTFCOO, 3K15 for BRCA1 BRCT D1840T/pSPTF-CONH2, and 3K16 for
BRCA1 BRCT D1840T/pSPTF-COO.SUPPLEMENTAL INFORMATION
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